United States Veterinary Ocular NSAIDs Market Size, by Product Classification (2024-2032)

In 2024, branded veterinary products were valued at USD 16,773.57 thousand, while generic veterinary products stood at USD 12,632.44 thousand, highlighting established adoption patterns in animal healthcare. Compounded drugs (custom formulations) were valued at USD 3,845.60 thousand, and off-label human use in veterinary ocular care accounted for USD 2,789.59 thousand. In 2025, the U.S. Veterinary Ocular Medicine Market is estimated to reach USD 17,472.57 thousand for branded products and USD 13,350.96 thousand for generics, reflecting steady growth across mainstream therapeutic categories and expanding clinical applications.

From 2026 to 2032, branded products are projected to reach USD 25,932.00 thousand, while generic products are expected to reach USD 21,930.52 thousand. Compounded formulations are anticipated to achieve USD 6,451.63 thousand, and off-label human ocular applications are projected at USD 4,484.33 thousand, indicating the increasing relevance of specialized treatments. These trends suggest that innovation in formulations and targeted therapies will drive expansion in the U.S. Veterinary Ocular Medicine Market, offering strategic opportunities for market players and advancing precision care in animal ophthalmology.